All In Biotech

Drug Trial Radar · NCT06843317

Safety and Immunogenicity Study of Revaccination With SCB-1019T in Healthy Adults

A Phase 1, Placebo-controlled, Randomized, Observer-blind Study to Describe the Safety, Tolerability and Immunogenicity of SCB-1019T in Adults Who Were Vaccinated With AREXVY at Least 18 Months Before

Last checked: Nov 19, 2026Latest source record: May 14, 2025 (this record)Source: ClinicalTrials.govMethods & limitations

RecruitingPivotal-lookingRandomized with 160 participants. This is a heuristic, not a regulatory label.

Status

Recruiting

Enrollment

160

Planned (sponsor's estimate)

Start

Mar 21, 2025

Primary completion

Mar 3, 2026

Study completion Jun 3, 2026

Sponsor

Sponsor type
Industry
First posted
Feb 24, 2025

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 1
Allocation
Randomized
Model
Parallel
Masking
Quadruple (participant, care provider, investigator, outcomes assessor)
Primary purpose
Prevention
FDA-regulated drug
Yes
Who can join
All sexes, from 60 years, up to 85 years
Healthy volunteers
Yes

Summary

As written by the sponsor on the registry.

CLO-SCB-1019-002 is the first study of SCB-1019T vaccine for revaccination in older adults who were previously vaccinated with AREXVY. The safety, tolerability and immunogenicity of SCB-1019T are assessed.

Conditions

  • RSV Infection

Interventions

  • Candidate vaccine, SCB-1019TBiological

    SCB-1019T is a novel bivalent recombinant RSV vaccine (CHO Cell) designed to broadly neutralize the two dominant circulating strains of the virus. The SCB-1019T vaccine consists of the PreF protein subunits from the two dominant circulating strains, strain A and strain B, fused to Trimer-Tag™.

  • AREXVYBiological

    positive comparator

  • placeboOther

    Placebo Comparator

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. To evaluate the safety and reactogenicity of revaccination with SCB-1019T vaccineTime frame: Within 7 days after vaccination
  2. To evaluate the safety and reactogenicity of revaccination with SCB-1019T vaccineTime frame: Within 28 days after vaccination
  3. To evaluate the safety and reactogenicity of revaccination with SCB-1019T vaccineTime frame: Throughout the study period, from enrollment to 6 months follow up

Locations

5 sites in 1 country. Site status is shown where the registry gives one.

  • AMR Phoenix

    Phoenix, Arizona · Recruiting

  • AMR Fort Myers

    Fort Myers, Florida · Recruiting

  • AMR Lexington

    Lexington, Kentucky · Recruiting

  • AMR Kansas City

    Kansas City, Missouri · Recruiting

  • Knoxville

    Knoxville, Tennessee · Recruiting

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.